Fierce Pharma

Marketing Sanofi Dupixent respiratory diseases Beyfortus Two years after its central role in the Paris Olympics in France, Sanofi is back in its native home once again supporting sport. Sanofi partnered with the Special Olympics Unified Football World Cup, held from July 6 to 11 in Paris, as an Official Health Partner. This is a tournament for footballers with and without intellectual disabilities and features 300 footballers from more than 20 nations.

Red-hot generative AI specialist Insilico Medicine has teamed up with another major biopharma player, this time linking up with CDMO Bora Pharmaceuticals. The collaboration, which could ultimately be worth $2.5 billion, the companies said, is another in a rush of drug discovery deals forged by Insilico. Others this year that have either joined forces or upped their ante with the 12-year-old Massachusetts biotech include Eli Lilly, Servier, Takeda and SK Biosciences.

The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that could become a new standard of care for patients with breast cancer. The regulator is allowing Celcuity to market gedatolisib, now called Revtorpyk, for previously treated patients with hormone receptor-positive, HER2-negative breast cancer without any mutations in the PIK3CA gene. Revtorpyk is used in combination with fulvestrant and with or without Pfizer’s Ibrance (palbociclib).

Partner Content Partnerships with Sites Multimedia Partner Content Hear from Senior Director Kate Woda as she breaks down what attendees can expect at the Partnerships with Sites Summit, including key themes, presenting companies, keynotes, networking opportunities and more. The Partnerships with Sites Summit will take place on September 14, 2026, in Boston, MA. Will We See You There? Click to Learn More Partnerships with Sites Multimedia Partner Content

In the second of a new series of interviews with top executives from leading healthcare and comms agencies, Fierce Pharma Marketing sat down with London-based Havas SO’s managing director, Joanna Quade and Creative Director, Lucy Doolan.

Huyabio has scored a win in the largest oncology study it has undertaken in its 22 years, as its oral histone deacetylase (HDAC) inhibitor HBI-8000 has succeeded in combination with Bristol Myers Squibb’s Opdivo in a phase 3 trial of patients with advanced skin cancer. The study, which included 404 melanoma patients in 15 countries, achieved its primary endpoint, as the combo produced a clinically meaningful improvement in progression-free survival.

After speedrunning a series of major manufacturing milestones in the past year and a half, the “biotech floodgates” have opened for Cellares, the automated cell therapy manufacturing specialist’s co-founder and CEO told Fierce Pharma Manufacturing.

Nearly a decade after spinning out its Chinese research hub to form Dizal Pharmaceutical, AstraZeneca is paying up to $1.5 billion to buy a piece of the pipeline, securing exclusive global rights for the biotech’s oral EGFR lung cancer drug Zegfrovy (sunvozertinib).

Real Chemistry has launched artificial intelligence tools for healthcare commercialization, continuing its embrace of technology tipped to transform biopharma marketing. The agency used proprietary and third-party data, large language models and orchestration platforms to create the AI offering.

Insulet’s wearable insulin patch Omnipod may be able to seamlessly control insulin delivery for patients with diabetes, but it can’t fill all mental health-related treatment gaps on its own. To broaden its network of personalized care offerings, the company is teaming up with mental health platform Calm to roll out a host of holistic "Mind in Range" resources.